What everyone is missing is the real connecting of the dots. It’s quite unfortunate IPIX is on the OTC. It has given a private company the ability to try and destroy their competitor with means of OTC tricks and some proxies. Do some DD, do some tech savvy snoops and you’ll be able to see why the negative interest exists here and why the “non shareholders” know so much about the science of two drugs looking for the same wide open market. It’s pretty simple.